Xiangdong Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiangdong Sun has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Bin Zhou
Department of Radiation Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People’s Republic of China
7 shared publicationsWei Ding
Department of Radiation Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People’s Republic of China
7 shared publicationsJiasheng Wang
Department of Radiation Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People’s Republic of China
6 shared publicationsWanrong Jiang
Department of Radiation Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People’s Republic of China
6 shared publicationsXiaoqin Ji
Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
6 shared publicationsHua Huang
Department of Radiation Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People’s Republic of China
4 shared publications
Latest Publications
- Open Access
- 8 April 2026
- Published by Frontiers Media SA in Frontiers in Sports and Active Living
- Vol. 8
Research advances in improving drug efficacy through remodeling of tumor vascular function by different aerobic exercises
Structural and functional abnormalities of tumor vasculature are key factors limiting drug delivery and therapeutic efficacy. This review aims to systematically summarize the mechanisms and evidence regarding how aerobic exercise improves drug delivery and enhances tumor treatment response by remodeling tumor vascular function. By synthesizing recent studies, we summarize the effects of different aerobic exercise modalities (intensity, duration, frequency) on tumor vasculature and the synergistic effects of combining exercise with pharmacotherapy. Aerobic exercise can increase pericyte coverage and enhance vascular stability, reduce vascular permeability and tumor interstitial fluid pressure (IFP) to improve drug penetration, enhance tumor blood flow perfusion and oxygenation to alleviate the hypoxic microenvironment, and modulate tumor metabolism and acid-base balance. These effects collectively promote the distribution and accumulation of drugs within tumor tissue, thereby enhancing treatment efficacy. The effects of exercise are influenced by its intensity, duration, frequency, and tumor type, with moderate-intensity, regular regimens (e.g., 3–5 times per week) being the most substantiated. Aerobic exercise serves as an effective non-pharmacological adjuvant that can significantly improve drug delivery and enhance anti-tumor treatment outcomes through multi-dimensional remodeling of tumor vascular function and the tumor microenvironment. Future prospective clinical studies, incorporating imaging and molecular biomarkers, are needed to further define optimal exercise protocols and their role in individualized integrated cancer therapy.
- 8 April 2026
- Published by Frontiers Media SA in Frontiers in Sports and Active Living
- Vol. 8
Open AccessResearch advances in improving drug efficacy through remodeling of tumor vascular function by different aerobic exercises
Structural and functional abnormalities of tumor vasculature are key factors limiting drug delivery and therapeutic efficacy. This review aims to systematically summarize the mechanisms and evidence regarding how aerobic exercise improves drug delivery and enhances tumor treatment response by remodeling tumor vascular function. By synthesizing recent studies, we summarize the effects of different aerobic exercise modalities (intensity, duration, frequency) on tumor vasculature and the synergistic effects of combining exercise with pharmacotherapy. Aerobic exercise can increase pericyte coverage and enhance vascular stability, reduce vascular permeability and tumor interstitial fluid pressure (IFP) to improve drug penetration, enhance tumor blood flow perfusion and oxygenation to alleviate the hypoxic microenvironment, and modulate tumor metabolism and acid-base balance. These effects collectively promote the distribution and accumulation of drugs within tumor tissue, thereby enhancing treatment efficacy. The effects of exercise are influenced by its intensity, duration, frequency, and tumor type, with moderate-intensity, regular regimens (e.g., 3–5 times per week) being the most substantiated. Aerobic exercise serves as an effective non-pharmacological adjuvant that can significantly improve drug delivery and enhance anti-tumor treatment outcomes through multi-dimensional remodeling of tumor vascular function and the tumor microenvironment. Future prospective clinical studies, incorporating imaging and molecular biomarkers, are needed to further define optimal exercise protocols and their role in individualized integrated cancer therapy.
- Open Access
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Sports and Active Living
- Vol. 8, 1768179
The role of exercise-induced myokines in cancer-associated inflammation and immune regulation: mechanisms and prospects
Skeletal muscle is increasingly recognized as an endocrine organ, and contraction-induced myokines are viewed as key mediators of the systemic benefits of exercise. This review synthesizes evidence on the roles and molecular mechanisms of major myokines—including IL-6, irisin, SPARC, oncostatin M (OSM), and decorin—in exercise-associated modulation of cancer-related inflammation and tumor progression. We propose two principal routes: direct effects on tumor cells (e.g., reduced proliferation and metastatic potential) and indirect effects mediated by remodeling of the tumor immune microenvironment. Nevertheless, the literature remains heterogeneous, and reported effects are strongly context dependent, contributing to ongoing debate. Personalized exercise prescriptions, together with deeper mechanistic studies, may accelerate the clinical translation of myokines as biomarkers and potential therapeutic targets.
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Sports and Active Living
- Vol. 8, 1768179
Open AccessThe role of exercise-induced myokines in cancer-associated inflammation and immune regulation: mechanisms and prospects
Skeletal muscle is increasingly recognized as an endocrine organ, and contraction-induced myokines are viewed as key mediators of the systemic benefits of exercise. This review synthesizes evidence on the roles and molecular mechanisms of major myokines—including IL-6, irisin, SPARC, oncostatin M (OSM), and decorin—in exercise-associated modulation of cancer-related inflammation and tumor progression. We propose two principal routes: direct effects on tumor cells (e.g., reduced proliferation and metastatic potential) and indirect effects mediated by remodeling of the tumor immune microenvironment. Nevertheless, the literature remains heterogeneous, and reported effects are strongly context dependent, contributing to ongoing debate. Personalized exercise prescriptions, together with deeper mechanistic studies, may accelerate the clinical translation of myokines as biomarkers and potential therapeutic targets.
- 9 March 2026
- Published by Wolters Kluwer Health in Health Physics
- Vol. 131 (4) , 281-292
Protective effect of memantine hydrochloride on radiation-induced cognitive impairment and its mechanism
Purpose: Ionizing radiation impairs cognition; safe mitigators are needed. Memantine shows clinical benefit during brain irradiation, but mechanisms are unclear. Methods: A mouse model of total-body irradiation injury was established via gamma rays with the establishment of control groups, irradiation groups, and irradiation+memantine groups. Bioinformatic analyses (target prediction, GO/KEGG enrichment, PPI hub identification) and molecular docking were used to nominate candidate targets and pathways for memantine’s radioprotection. Guided by these results, hippocampal levels of nitric oxide (NO), peroxynitrite (ONOO − ), inducible nitric oxide synthase (iNOS), and β-amyloid (Aβ42) were quantified. Results: Memantine improved behavioral performance post-irradiation. Enrichment highlighted neuroactive ligand–receptor interaction and calcium signaling; docking prioritized CYP2D6 and DRD2. In hippocampus, memantine reduced radiation-induced increases in NO, ONOO − , iNOS, and Aβ42. Conclusion: Memantine hydrochloride attenuates acute radiation-related cognitive deficits, potentially via modulation of synaptic signaling and suppression of nitrosative stress and Aβ42 accumulation. Findings will be interpreted as generating hypotheses that motivate subsequent mechanistic experiments and preliminary translational work.
- 9 March 2026
- Published by Wolters Kluwer Health in Health Physics
- Vol. 131 (4) , 281-292
Protective effect of memantine hydrochloride on radiation-induced cognitive impairment and its mechanism
Purpose: Ionizing radiation impairs cognition; safe mitigators are needed. Memantine shows clinical benefit during brain irradiation, but mechanisms are unclear. Methods: A mouse model of total-body irradiation injury was established via gamma rays with the establishment of control groups, irradiation groups, and irradiation+memantine groups. Bioinformatic analyses (target prediction, GO/KEGG enrichment, PPI hub identification) and molecular docking were used to nominate candidate targets and pathways for memantine’s radioprotection. Guided by these results, hippocampal levels of nitric oxide (NO), peroxynitrite (ONOO − ), inducible nitric oxide synthase (iNOS), and β-amyloid (Aβ42) were quantified. Results: Memantine improved behavioral performance post-irradiation. Enrichment highlighted neuroactive ligand–receptor interaction and calcium signaling; docking prioritized CYP2D6 and DRD2. In hippocampus, memantine reduced radiation-induced increases in NO, ONOO − , iNOS, and Aβ42. Conclusion: Memantine hydrochloride attenuates acute radiation-related cognitive deficits, potentially via modulation of synaptic signaling and suppression of nitrosative stress and Aβ42 accumulation. Findings will be interpreted as generating hypotheses that motivate subsequent mechanistic experiments and preliminary translational work.
- Open Access
- 7 November 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1493773
Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Background: Lung cancer is a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. While immune checkpoint inhibitors (ICIs) have transformed treatment for advanced NSCLC, the role of bone metastasis in modulating ICI efficacy remains unclear. Bone metastasis, occurring in 30-40% of advanced NSCLC cases, is associated with worse outcomes. However, how this affects the therapeutic benefit of ICIs has not been fully elucidated, highlighting a critical knowledge gap in optimizing treatment for this patient population.Methods: A comprehensive literature search across multiple databases, including PubMed, Embase, and Cochrane, identified 13 studies with a total of 3,681 patients, of whom 37.6% had bone metastasis. Overall survival (OS) and progression-free survival (PFS) were compared between NSCLC patients with and without bone metastasis. Data were analyzed using a random-effects model to account for study heterogeneity.Results: The meta-analysis demonstrated that bone metastasis significantly worsened overall survival (OS) and progression-free survival (PFS) in NSCLC patients treated with ICIs. Specifically, bone metastasis was associated with a 45% increased risk of death (HR: 1.45, 95% CI: 1.30–1.62, p < 0.001) and a 40% increased risk of disease progression (HR: 1.40, 95% CI: 1.25–1.58, p < 0.001). No statistically significant impact on PFS was observed. (HR: 1.28, 95% CI: 0.77–2.10, p = 0.34). High heterogeneity was observed in some subgroup analyses (I² = 72%), indicating variability in the results.Conclusion: Bone metastasis is a significant negative prognostic factor for NSCLC patients treated with ICIs, associated with a higher risk of mortality and disease progression. These results underscore the importance of tailored treatment approaches for NSCLC patients with bone metastasis and call for further research to optimize therapy outcomes in this group.
- 7 November 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1493773
Open AccessImpact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Background: Lung cancer is a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. While immune checkpoint inhibitors (ICIs) have transformed treatment for advanced NSCLC, the role of bone metastasis in modulating ICI efficacy remains unclear. Bone metastasis, occurring in 30-40% of advanced NSCLC cases, is associated with worse outcomes. However, how this affects the therapeutic benefit of ICIs has not been fully elucidated, highlighting a critical knowledge gap in optimizing treatment for this patient population.Methods: A comprehensive literature search across multiple databases, including PubMed, Embase, and Cochrane, identified 13 studies with a total of 3,681 patients, of whom 37.6% had bone metastasis. Overall survival (OS) and progression-free survival (PFS) were compared between NSCLC patients with and without bone metastasis. Data were analyzed using a random-effects model to account for study heterogeneity.Results: The meta-analysis demonstrated that bone metastasis significantly worsened overall survival (OS) and progression-free survival (PFS) in NSCLC patients treated with ICIs. Specifically, bone metastasis was associated with a 45% increased risk of death (HR: 1.45, 95% CI: 1.30–1.62, p < 0.001) and a 40% increased risk of disease progression (HR: 1.40, 95% CI: 1.25–1.58, p < 0.001). No statistically significant impact on PFS was observed. (HR: 1.28, 95% CI: 0.77–2.10, p = 0.34). High heterogeneity was observed in some subgroup analyses (I² = 72%), indicating variability in the results.Conclusion: Bone metastasis is a significant negative prognostic factor for NSCLC patients treated with ICIs, associated with a higher risk of mortality and disease progression. These results underscore the importance of tailored treatment approaches for NSCLC patients with bone metastasis and call for further research to optimize therapy outcomes in this group.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 1557-1570
A Comparison of Stereotactic Radiation Therapy in Elderly Patients with Central or Peripheral Stage I-II (T1-3 N0 M0) Non-Small Cell Lung Cancer
Purpose: The objective of this study was to compare the clinical outcomes of stereotactic body radiation therapy (SBRT) in elderly patients aged 65 or older with clinical stage I–II non-small-cell lung cancer (NSCLC), specifically examining the differences between centrally located lung tumors and peripherally located lung tumors. Methods: From April 2009 to January 2020, a total of 136 patients with 136 tumors (65 central, 71 peripheral; NSCLC) at an early stage (T1-3N0M0) were treated with SBRT at a single institution. Central/peripheral location was assessed retrospectively on planning CT scans. A propensity score matching analysis was utilized to compare the two groups. In addition, the prognosis and related toxicity were compared between the two study arms. Results: A total of 33 central tumors and 33 peripheral tumors were matched and analyzed. The results showed no significant differences in overall survival (OS) and progression-free survival (PFS) between the two groups. The 2-year OS was 71.88% (95% CI, 57.87%-89.27%) in the central lung cancer group, while it was 93.94% (95% CI, 86.14%-100.00%) in the peripheral lung cancer group (P=0.462). The 2-year PFS was 43.75% in the central lung cancer group, while it was 78.79% in the peripheral lung cancer group (P=0.279). Further subgroup analysis indicated that the location of peripheral tumor have a positive impact on OS in patients with adenocarcinoma. The occurrence of local failure, regional failure, or distant failure was comparable between central and peripheral tumors. There was no statistically significant difference in toxicity between the central and the peripheral tumor groups. Conclusion: The outcomes of SBRT for central tumors versus peripheral lung tumors in elderly patients with early-stage NSCLC were similar. SBRT demonstrated a similar level of safety in terms of toxicity for both central and peripheral lung tumors.
- 1 November 2024
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 1557-1570
Open AccessA Comparison of Stereotactic Radiation Therapy in Elderly Patients with Central or Peripheral Stage I-II (T1-3 N0 M0) Non-Small Cell Lung Cancer
Purpose: The objective of this study was to compare the clinical outcomes of stereotactic body radiation therapy (SBRT) in elderly patients aged 65 or older with clinical stage I–II non-small-cell lung cancer (NSCLC), specifically examining the differences between centrally located lung tumors and peripherally located lung tumors. Methods: From April 2009 to January 2020, a total of 136 patients with 136 tumors (65 central, 71 peripheral; NSCLC) at an early stage (T1-3N0M0) were treated with SBRT at a single institution. Central/peripheral location was assessed retrospectively on planning CT scans. A propensity score matching analysis was utilized to compare the two groups. In addition, the prognosis and related toxicity were compared between the two study arms. Results: A total of 33 central tumors and 33 peripheral tumors were matched and analyzed. The results showed no significant differences in overall survival (OS) and progression-free survival (PFS) between the two groups. The 2-year OS was 71.88% (95% CI, 57.87%-89.27%) in the central lung cancer group, while it was 93.94% (95% CI, 86.14%-100.00%) in the peripheral lung cancer group (P=0.462). The 2-year PFS was 43.75% in the central lung cancer group, while it was 78.79% in the peripheral lung cancer group (P=0.279). Further subgroup analysis indicated that the location of peripheral tumor have a positive impact on OS in patients with adenocarcinoma. The occurrence of local failure, regional failure, or distant failure was comparable between central and peripheral tumors. There was no statistically significant difference in toxicity between the central and the peripheral tumor groups. Conclusion: The outcomes of SBRT for central tumors versus peripheral lung tumors in elderly patients with early-stage NSCLC were similar. SBRT demonstrated a similar level of safety in terms of toxicity for both central and peripheral lung tumors.
- 16 September 2024
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (8) , 102067
Development and validation of a prognostic nomogram in patients aged ≥65 years with stage I-II non-small cell lung cancer treated with stereotactic body radiotherapy
- 16 September 2024
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (8) , 102067
Development and validation of a prognostic nomogram in patients aged ≥65 years with stage I-II non-small cell lung cancer treated with stereotactic body radiotherapy
- Open Access
- 13 May 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1235630
Efficacy and safety of stereotactic radiotherapy on elderly patients with stage I-II central non-small cell lung cancer
Background: Many studies demonstrated the safety and efficacy of SBRT in the treatment of elderly patients with early-stage non-small cell lung cancer (NSCLC). However, those studies focused on patients with peripheral lung cancer. This study aimed to evaluate the clinical efficacy and toxicity of SBRT in elderly patients with stage I-II central NSCLC in single institution.Methods: From April 2009 to January 2020, a retrospective study was conducted on patients ≥ 65 years old with stage I-II NSCLC that was centrally localized and treated with SBRT at a single institution. Absolute C-reactive protein (CRP)/albumin ratio (CAR) and body mass index (BMI) recorded at pretreatment were analyzed. Endpoints included overall survival (OS), progression-free survival (PFS), cancer-specific death, noncancer-specific death, local progression (LP) and distant progression (DP).Results: Stereotactic body radiation treatment (SBRT) was administered to a total of 44 patients. The most common dose fractionation schedule was 60 Gy given in 5 fractions. The median PFS of the cohort was 31 months (95% CI, 19.47–42.53 months). The median OS of all patients was 69 months (95% CI, 33.8–104.2 months). The median time to noncancer-specific death was 54.5 months. The median time to cancer-specific death was 36 months. The cumulative incidences of cancer-specific death at 1 year, 5 years, and 10 years were 11.63% (95%CI, 4.2–23.23%), 42.99% (95%CI, 27.56–57.53%), and 65.94% (95%CI, 45.76–80.1%), respectively. pre-SBRT BMI of ≤ 22.77 (HR 4.60, 95% CI 1.84–11.51, P=0.001) and pre-SBRT CAR of ≤0.91 (HR 5.19, 95% CI 2.15–12.52, P<0.000) were significant predictors of higher OS on multivariable analysis. The median times to LP and DP were 10 months and 11 months, respectively. In terms of acute toxicity, grade 1 including cough (38.64%), radiation pneumonitis (29.55%), anemia (25%), and fatigue (20.45%) was often observed. There was no evidence of grade 4 or 5 acute toxicity. In terms of late toxicity, 2 patients developed grade 1 pulmonary fibrosis during follow-up.Conclusion: This study showed that SBRT can effectively control local tumor progression, and have acceptable toxicity for elderly patients with centrally located stage I-II NSCLC. Lower pre-SBRT BMI and lower pre-SBRT CAR were associated with a decreased risk of cancer-specific death.
- 13 May 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1235630
Open AccessEfficacy and safety of stereotactic radiotherapy on elderly patients with stage I-II central non-small cell lung cancer
Background: Many studies demonstrated the safety and efficacy of SBRT in the treatment of elderly patients with early-stage non-small cell lung cancer (NSCLC). However, those studies focused on patients with peripheral lung cancer. This study aimed to evaluate the clinical efficacy and toxicity of SBRT in elderly patients with stage I-II central NSCLC in single institution.Methods: From April 2009 to January 2020, a retrospective study was conducted on patients ≥ 65 years old with stage I-II NSCLC that was centrally localized and treated with SBRT at a single institution. Absolute C-reactive protein (CRP)/albumin ratio (CAR) and body mass index (BMI) recorded at pretreatment were analyzed. Endpoints included overall survival (OS), progression-free survival (PFS), cancer-specific death, noncancer-specific death, local progression (LP) and distant progression (DP).Results: Stereotactic body radiation treatment (SBRT) was administered to a total of 44 patients. The most common dose fractionation schedule was 60 Gy given in 5 fractions. The median PFS of the cohort was 31 months (95% CI, 19.47–42.53 months). The median OS of all patients was 69 months (95% CI, 33.8–104.2 months). The median time to noncancer-specific death was 54.5 months. The median time to cancer-specific death was 36 months. The cumulative incidences of cancer-specific death at 1 year, 5 years, and 10 years were 11.63% (95%CI, 4.2–23.23%), 42.99% (95%CI, 27.56–57.53%), and 65.94% (95%CI, 45.76–80.1%), respectively. pre-SBRT BMI of ≤ 22.77 (HR 4.60, 95% CI 1.84–11.51, P=0.001) and pre-SBRT CAR of ≤0.91 (HR 5.19, 95% CI 2.15–12.52, P<0.000) were significant predictors of higher OS on multivariable analysis. The median times to LP and DP were 10 months and 11 months, respectively. In terms of acute toxicity, grade 1 including cough (38.64%), radiation pneumonitis (29.55%), anemia (25%), and fatigue (20.45%) was often observed. There was no evidence of grade 4 or 5 acute toxicity. In terms of late toxicity, 2 patients developed grade 1 pulmonary fibrosis during follow-up.Conclusion: This study showed that SBRT can effectively control local tumor progression, and have acceptable toxicity for elderly patients with centrally located stage I-II NSCLC. Lower pre-SBRT BMI and lower pre-SBRT CAR were associated with a decreased risk of cancer-specific death.
- Open Access
- 25 October 2023
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1279157
Unveiling the intricate causal nexus between pancreatic cancer and peripheral metabolites through a comprehensive bidirectional two-sample Mendelian randomization analysis
Aim: Pancreatic cancer (PC) is a devastating malignancy characterized by its aggressive nature and poor prognosis. However, the relationship of PC with peripheral metabolites remains not fully investigated. The study aimed to explore the causal linkage between PC and peripheral metabolite profiles.Methods: Employing publicly accessible genome-wide association studies (GWAS) data, we conducted a bidirectional two-sample Mendelian randomization (MR) analysis. The primary analysis employed the inverse-variance weighted (IVW) method. To address potential concerns about horizontal pleiotropy, we also employed supplementary methods such as maximum likelihood, weighted median, MR-Egger regression, and MR pleiotropy residual sum and outlier (MR-PRESSO).Results: We ascertained 20 genetically determined peripheral metabolites with causal linkages to PC while high-density lipoprotein (HDL) and very low-density lipoprotein (VLDL) particles accounted for the vast majority. Specifically, HDL particles exhibited an elevated PC risk while VLDL particles displayed an opposing pattern. The converse MR analysis underscored a notable alteration in 17 peripheral metabolites due to PC, including branch chain amino acids and derivatives of glycerophospholipid. Cross-referencing the bidirectional MR results revealed a reciprocal causation of PC and X-02269 which might form a self-perpetuating loop in PC development. Additionally, 1-arachidonoylglycerophosphocholine indicated a reduced PC risk and an increase under PC influence, possibly serving as a negative feedback regulator.Conclusion: Our findings suggest a complex interplay between pancreatic cancer and peripheral metabolites, with potential implications for understanding the etiology of pancreatic cancer and identifying novel early diagnosis and therapeutic targets. Moreover, X-02269 may hold a pivotal role in PC onset and progression.
- 25 October 2023
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1279157
Open AccessUnveiling the intricate causal nexus between pancreatic cancer and peripheral metabolites through a comprehensive bidirectional two-sample Mendelian randomization analysis
Aim: Pancreatic cancer (PC) is a devastating malignancy characterized by its aggressive nature and poor prognosis. However, the relationship of PC with peripheral metabolites remains not fully investigated. The study aimed to explore the causal linkage between PC and peripheral metabolite profiles.Methods: Employing publicly accessible genome-wide association studies (GWAS) data, we conducted a bidirectional two-sample Mendelian randomization (MR) analysis. The primary analysis employed the inverse-variance weighted (IVW) method. To address potential concerns about horizontal pleiotropy, we also employed supplementary methods such as maximum likelihood, weighted median, MR-Egger regression, and MR pleiotropy residual sum and outlier (MR-PRESSO).Results: We ascertained 20 genetically determined peripheral metabolites with causal linkages to PC while high-density lipoprotein (HDL) and very low-density lipoprotein (VLDL) particles accounted for the vast majority. Specifically, HDL particles exhibited an elevated PC risk while VLDL particles displayed an opposing pattern. The converse MR analysis underscored a notable alteration in 17 peripheral metabolites due to PC, including branch chain amino acids and derivatives of glycerophospholipid. Cross-referencing the bidirectional MR results revealed a reciprocal causation of PC and X-02269 which might form a self-perpetuating loop in PC development. Additionally, 1-arachidonoylglycerophosphocholine indicated a reduced PC risk and an increase under PC influence, possibly serving as a negative feedback regulator.Conclusion: Our findings suggest a complex interplay between pancreatic cancer and peripheral metabolites, with potential implications for understanding the etiology of pancreatic cancer and identifying novel early diagnosis and therapeutic targets. Moreover, X-02269 may hold a pivotal role in PC onset and progression.
- 19 June 2023
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 27 (5) , 425-433
Application of intraoperative radiotherapy for malignant glioma
- 19 June 2023
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 27 (5) , 425-433
Application of intraoperative radiotherapy for malignant glioma
- RetractedOpen Access
- 17 February 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1095362
RETRACTED: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
Introduction: Anlotinib, a novel multi-kinase inhibitor, was found to improve progression-free survival (PFS) in brain metastases.Methods: This paper retrospectively analyzed 26 newly diagnosed or recurrent high-grade gliomas from 2017 to 2022, and the patients received oral anlotinib during concurrent postoperative chemoradiotherapy or after recurrence. Efficacy was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria, and the main study endpoints were PFS at 6 months and overall survival (OS) at 1 year.Results: After the follow-up, until May 2022, 13 patients survived and 13 patients died, with a median follow-up time of 25.6 months. The disease control rate (DCR) was 96.2% (25/26), and the overall response rate (ORR) rate was 73.1% (19/26). The median PFS after oral anlotinib was 8.9 months (0.8–15.1), and the PFS at 6 months was 72.5%. The median OS after oral anlotinib was 12 months (1.6–24.4), and the OS at 12 months was 42.6%. Anlotinib-related toxicities were observed in 11 patients, mostly grades 1–2. In the multivariate analysis, patients with Karnofsky Performance Scale (KPS) above 80 had a highermedian PFS of 9.9months (p = 0.02), and their sex, age, IDH mutation, MGMTmethylation, and whether anlotinib was combined with chemoradiotherapy or maintenance treatment had no effect on PFS.Conclusion: We found that anlotinib combined with chemoradiotherapy in treating high-grade central nervous system (CNS) tumors can prolong PFS and OS and that it was safe.
- 17 February 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1095362
RetractedOpen AccessRETRACTED: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
Introduction: Anlotinib, a novel multi-kinase inhibitor, was found to improve progression-free survival (PFS) in brain metastases.Methods: This paper retrospectively analyzed 26 newly diagnosed or recurrent high-grade gliomas from 2017 to 2022, and the patients received oral anlotinib during concurrent postoperative chemoradiotherapy or after recurrence. Efficacy was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria, and the main study endpoints were PFS at 6 months and overall survival (OS) at 1 year.Results: After the follow-up, until May 2022, 13 patients survived and 13 patients died, with a median follow-up time of 25.6 months. The disease control rate (DCR) was 96.2% (25/26), and the overall response rate (ORR) rate was 73.1% (19/26). The median PFS after oral anlotinib was 8.9 months (0.8–15.1), and the PFS at 6 months was 72.5%. The median OS after oral anlotinib was 12 months (1.6–24.4), and the OS at 12 months was 42.6%. Anlotinib-related toxicities were observed in 11 patients, mostly grades 1–2. In the multivariate analysis, patients with Karnofsky Performance Scale (KPS) above 80 had a highermedian PFS of 9.9months (p = 0.02), and their sex, age, IDH mutation, MGMTmethylation, and whether anlotinib was combined with chemoradiotherapy or maintenance treatment had no effect on PFS.Conclusion: We found that anlotinib combined with chemoradiotherapy in treating high-grade central nervous system (CNS) tumors can prolong PFS and OS and that it was safe.